Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
about
Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.Romiplostim dose response in patients with immune thrombocytopenia.The pharmacology and clinical application of thrombopoietin receptor agonists.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeysInterpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsComparative performance of cell life span and cell transit models for describing erythropoietic drug effectsModel Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Lifespan based indirect response models.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.
P2860
Q33396650-8DB27CF6-5461-40FD-B58D-33AA780ECCC6Q33398730-07FBA446-BDB5-4455-AB70-80ADC930C68CQ33417700-7A46FA3F-F678-4DA6-9DFE-B00FCAB07452Q34293586-F4D60BA1-EA00-4A3B-873F-2CBC49CFD8A2Q34293733-7EA901B8-A805-457F-BE21-233C4762906AQ35226129-D470B3B4-0589-4CF7-BDBD-266E8B94AE6CQ35595803-EBEE0D70-551E-469A-ADBB-F2361C8863C0Q36203402-9EAE39C8-8D20-4911-9D6B-C020F641BB2CQ36354544-4E32DDCD-3EFA-4808-A3EA-171DD063E136Q37972792-34CB20AF-EAD7-44B8-BB1D-A163EEC343BDQ38110433-2AE7FB07-A306-4581-A065-8FC215B4FEF8Q38241696-B02F19F1-AF18-43C1-98AE-1ABC9EE62BA8Q38274487-3004CA3A-9BE8-4FF3-97C8-413B44A148C1Q39746668-624DD5E3-E5B3-497C-B26B-B718173B7784Q41928814-E131D37D-3FC4-4891-B4AB-F442EFF58CA5Q42351659-2BF6752B-045A-4132-83B4-6DDA24C3CB5FQ43635728-BDAA056E-04B8-4E29-BFE8-614697822A83Q46358056-44140AD6-A532-4781-B7E7-76B3B32377A3
P2860
Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@en
type
label
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@en
prefLabel
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@ast
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@en
P2093
P2860
P356
P1476
Pharmacokinetic and pharmacody ...... istration in healthy subjects.
@en
P2093
Dirk Cerneus
Juan Jose Perez-Ruixo
Kathryn H Brown
Mahesh N Samtani
P2860
P304
P356
10.1177/0091270008329559
P577
2009-03-01T00:00:00Z